



18 July 2007

Announcement to the Singapore Exchange

GERMAN PATENT OFFICE UPHOLDS LMA'S IP AGAINST AMBU CHALLENGE

Mainboard-listed LMA International NV ("LMA"), the global leader in the development and marketing of the LMA™ range of supraglottic airway management devices, is pleased to announce that the German Patent Office has upheld its intellectual property right – German Utility Model DE 299 24 738 – against a challenge by Danish competitor Ambu A/S ("Ambu"). This IP right protects LMA's invention of a reinforced tip on supraglottic airway devices.

In a separate court action, LMA's wholly-owned subsidiary, LMA Deutschland GmbH, had earlier obtained a judgment in Germany that Ambu's airway devices infringe LMA's invention. LMA is seeking €3.1 million in damages from Ambu for its infringement in Germany. The decision of the German Patent Office ensures that LMA's damages claim action will proceed. That action is currently scheduled to be heard in August 2007.

LMA has additional patent infringement actions pending against Ambu in France and the Netherlands to protect the same invention and currently has the legal right to commence similar actions in other markets.

LMA expects Ambu to appeal the German Patent Office's decision, as it has appealed the German court's judgment of infringement.

LMA International NV
PO Box 862, Osprey House, Old Street, Jersey, Channel Islands JE4 2ZZ

ENDS

FOR FURTHER INFORMATION, PLEASE CONTACT:

Maria Gianoutsos, LMA International NV, +44 (0)1923 841756
Sharon Seetho, Gavin Anderson & Company, Singapore, +65 9009 8495

NOTES:

LMA International NV

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

LMA™ Airways

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

LMA Patent Portfolio

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 335 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.